Payment overview · 2025
General Payments
$1,517.73
88 reported records · 18 companies
Healthcare provider profile · identity verified
Yasser William Barsoum, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · VISALIA, CA · NPI 1467618363
Verified facts
What the public records show
CMS Open Payments records show Yasser William Barsoum, MD received $1,517.73 in general payments during 2025 across 88 reported records.
Ardelyx, Inc. accounted for 17.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Velphoro.
Fresenius USA Marketing, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VELPHORO as an associated drug or biological on 8763 records involving 2642 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Velphoro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $257.92 | 17.0% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $216.96 | 14.3% | 20 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $165.84 | 10.9% | 7 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $151.65 | 10.0% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $119.76 | 7.9% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $88.69 | 5.8% | 4 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $82.44 | 5.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.99 | 4.2% | 3 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $60.50 | 4.0% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.01 | 3.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $51.00 | 3.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.13 | 3.0% | 2 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.84 | 2.8% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $29.89 | 2.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.08 | 1.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.50 | 1.4% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $18.28 | 1.2% | 1 | 2025 |
| CorMedix Inc. | Unresolved — no canonical attribution shown | $18.25 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,453.19 | 86 |
| Education | $64.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $257.92 | 18 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $165.84 | 7 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $151.65 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $140.35 | 15 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $118.62 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $88.69 | 4 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $82.44 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $76.61 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.54 | 2 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $60.50 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $57.01 | 2 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $45.13 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.04 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.04 | 2 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $29.89 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.08 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| DEFENCATH Normalized: defencath |
Drug | CorMedix Inc. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 134 | exact normalized | Medicare Part D |
| VELPHORO velphoro |
2025 | Velphoro | 2024 | 29 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Fresenius USA Marketing, Inc. Exact reporting entity; no affiliate inference |
2025 | VELPHORO open payments reported associated product |
CMS Open Payments — General Payments 8763 supporting records · 2642 recipient NPIs · example record 1244803773 |
Velphoro · 2024 Exact normalized brand match · 1 Part D row |
29 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
134 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 417 | 148 |
| Lisinopril | Lisinopril | 253 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 224 | 71 |
| Alprazolam | Alprazolam | 220 | 65 |
| Bumetanide | Bumetanide | 177 | 71 |
| Prosol | Parenteral Amino Acid 20% No.1 | 172 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 168 | 58 |
| Calcitriol | Calcitriol | 140 | 66 |
| Cinacalcet Hcl | Cinacalcet Hcl | 137 | 46 |
| Ozempic | Semaglutide | 134 | 28 |
| Clinolipid | Fat Emulsion/Olive/Soy/Phospho | 133 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 132 | 49 |
| Losartan Potassium | Losartan Potassium | 124 | 38 |
| Sevelamer Carbonate | Sevelamer Carbonate | 122 | 42 |
| Carvedilol | Carvedilol | 119 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 45 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 100 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 40 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 98 | 58 |
| Allopurinol | Allopurinol | 82 | 28 |
| Minoxidil | Minoxidil | 78 | 28 |
| Lokelma | Sodium Zirconium Cyclosilicate | 71 | 36 |
| Prednisone | Prednisone | 70 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 29 |
| Retacrit | Epoetin Alfa-Epbx | 64 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 32 |
| Midodrine Hcl | Midodrine Hcl | 63 | 24 |
| Megestrol Acetate | Megestrol Acetate | 54 | 30 |
| Repatha Sureclick | Evolocumab | 54 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | 17 |
| Gemfibrozil | Gemfibrozil | 50 | 19 |
| Tramadol Hcl | Tramadol Hcl | 50 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | 16 |
| Azithromycin | Azithromycin | 48 | 28 |
| Clonidine Hcl | Clonidine Hcl | 47 | 19 |
| Gabapentin | Gabapentin | 46 | 21 |
| Potassium Chloride | Potassium Chloride | 46 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | suppressed |
| Valsartan | Valsartan | 43 | 15 |
| Januvia | Sitagliptin Phosphate | 41 | 12 |
| Lactulose | Lactulose | 39 | 24 |
| Nifedipine Er | Nifedipine | 39 | 14 |
| Eliquis | Apixaban | 35 | 11 |
| Calcium Acetate | Calcium Acetate | 34 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 34 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 19 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Omeprazole | Omeprazole | 33 | 15 |
| Chlorthalidone | Chlorthalidone | 31 | 11 |
| Furosemide | Furosemide | 31 | 14 |
| Metolazone | Metolazone | 31 | 12 |
| Repatha Syringe | Evolocumab | 30 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 29 | 14 |
| Potassium Citrate Er | Potassium Citrate | 28 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 16 |
| Sertraline Hcl | Sertraline Hcl | 27 | 15 |
| Spironolactone | Spironolactone | 27 | 13 |
| Clinisol | Parenteral Amino Acid 15% No.5 | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 18 |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Procrit | Epoetin Alfa | 23 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 15 |
| Cephalexin | Cephalexin | 19 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Xphozah | Tenapanor Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Metformin Hcl | Metformin Hcl | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Paricalcitol | Paricalcitol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,517.73 · 88 records | Ardelyx, Inc. | ACTHAR, CRYSVITA, DEFENCATH, FREESTYLE LIBRE 3, Fabhalta, IBSRELA, JARDIANCE, JYNARQUE, Kerendia, MOUNJARO, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, REPATHA, TARPEYO, TAVNEOS, VELPHORO, VOQUEZNA, Vafseo, Vanrafia, Veltassa, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Fresenius USA Marketing, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error